Key result
Pre-procedural levosimendan shows no short-term adverse events in high-risk ACS patients with HFrEF undergoing PCI.
Why the study?
Is pre-procedural levosimendan safe and associated with favorable short-term outcomes in patients with reduced LVEF undergoing high-risk PCI for ACS?
Observational (n=90)
Is pre-procedural levosimendan safe and associated with favorable short-term outcomes in patients with reduced LVEF undergoing high-risk PCI for ACS?
Answers are grounded in this paper and cite their sources.
Pre-procedural levosimendan appears to be a relatively safe approach with low rates of in-hospital adverse events for patients with reduced LVEF undergoing high-risk PCI for ACS.
Background/Objectives: Current evidence suggests that levosimendan may have a beneficial effect in the treatment of acute heart failure (AHF) or cardiogenic shock following primary percutaneous coronary intervention (PCI). However, there is a paucity of data on the use of levosimendan prior to PCI. Therefore, our pilot study aimed to assess the short-term prognosis of a new therapeutic protocol involving preprocedural infusion of levosimendan in patients with reduced left ventricular ejection fraction undergoing high-risk PCI for acute coronary syndrome (ACS). Methods: The study is a retrospective observational study, and the population includes all subjects who received levosimendan infusion prior to high-risk PCI for ACS. Subjects requiring urgent revascularization (cardiogenic shock, cardiac arrest) or with mechanical complications of ACS were excluded. Results: The study cohort consisted of 90 subjects, predominantly men (91.1%) with significantly reduced left ventricular function (28.7% (12)) and advanced coronary artery disease, mean SYNTAX Score 25.8 (19.3–33). During in-hospital follow-up, we observed 2 primary outcomes—death. The major adverse cardiac and cerebrovascular events (MACCE) rate was 7.8%. Two clinical adverse events that did not lead to discontinuation were observed during the in-hospital period. Both were related to hypotension. Conclusions: In short-term observation, novel therapeutic approach in the management of high-risk PCI in ACS patients—pre-procedural levosimendan—was a relatively safe approach. No significant adverse events were reported.
No takes yet. Share an insight, caveat, or question.
Turkiewicz et al. (2025) conducted an observational in Acute coronary syndrome with reduced left ventricular ejection fraction undergoing high-risk PCI (n=90). Pre-procedural levosimendan was evaluated on death. Pre-procedural levosimendan infusion in patients with reduced ejection fraction undergoing high-risk PCI for ACS was associated with a 2.2% in-hospital mortality rate and a 7.8% MACCE rate.
Synapse has enriched 10 related papers. Consider them for comparative context: